SUSMED, Inc. (4263) Stock Price

Susmed is a company focused on developing digital therapeutics (DTx), providing therapeutic apps and IT platforms that support their commercialization and clinical development. The company has obtained regulatory approval under Japan's Pharmaceutical Affairs Law for a therapeutic app treating insomnia, and is expanding its services based on experience in app development and clinical validation.

Its primary customers are pharmaceutical companies, academic research institutions, healthcare providers, and CROs. For these customers, the company implements clinical trial systems and medical data analysis platforms to improve efficiency in clinical development and real-world data (RWD) analysis. Revenue comes primarily from therapeutic app sales and licensing, clinical trial system implementation and operation fees, cloud-based analytics service subscriptions, and development support and contract research services.

The business consists of two main pillars: the "DTx Product Business" and the "DTx Platform Business." The former focuses on developing therapeutic apps targeting regulatory approval, with multiple pipelines including insomnia treatment, exercise therapy for cancer patients, and palliative care support. The latter provides systems for conducting clinical trials remotely and safely (featuring identity verification and data integrity functions) and machine learning-based automated analysis platforms emphasizing explainability (RWD analysis cloud services), aiming to streamline clinical research and drug development processes for companies and research institutions.

Susmed focuses on Digital Therapeutics (DTx) as its core business, pursuing growth through two pillars: commercializing therapeutic apps and operating a clinical development platform that supports them. Rather than setting traditional financial targets such as revenue and ROE, the company manages key performance indicators including the number of development pipeline projects and clinical trial progress for its product business, and contract volume for its platform business. Over the long term, it aims to maximize revenue through these metrics. The company has already obtained regulatory approval for a therapeutic app for insomnia treatment, and securing additional approvals and insurance coverage remain near-term sales objectives.

Priority investment areas are therapeutic app development and IT infrastructure to streamline clinical research. For therapeutic apps, the company is establishing investment criteria to selectively concentrate resources at each stage of clinical trials, with a focus on projects with high revenue potential. The company also holds patents on clinical trial systems and apps, which serve as competitive differentiators. On the platform side, the company is investing to enhance reliability in actual operations, with regulatory compliance in mind, aiming to popularize systems that eliminate the need for on-site trial monitoring.

For market expansion and business growth, the company is advancing joint research and deployment expansion domestically and internationally with pharmaceutical companies, academic institutions, healthcare providers, and contract research organizations (CROs) as primary customers. Specific initiatives include leveraging the management team's industry networks to identify promising projects, conducting outreach based on results from government sandbox programs, and exploring licensing arrangements and partnerships to accelerate revenue generation. Additionally, the company prioritizes procedures and negotiations for insurance coverage, with a plan to ensure market entry and revenue realization following regulatory approval.

Technology innovation efforts center on developing automated analysis systems using machine learning and accumulating real-world clinical data. By analyzing real-world data to discover new therapeutic opportunities, and continuously enhancing the analysis platform's functionality and user interface, the company aims to increase contract acquisition and customer value. Across clinical trials, the company seeks to realize quality improvements—such as streamlining participant recruitment and preventing data loss—through its systems, ultimately contributing to cost reduction in drug development for pharmaceutical companies.